<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717427</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1165</org_study_id>
    <nct_id>NCT04717427</nct_id>
  </id_info>
  <brief_title>Longitudinal Studies to Identify Biomarkers for Sturge-Weber Syndrome</brief_title>
  <official_title>Integrated Longitudinal Studies to Identify Biomarkers and Therapeutic Strategies for Sturge-Weber Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sturge-Weber Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Individuals with Sturge-Weber Syndrome (SWS) sometimes have brain involvement which can&#xD;
      result in seizures, stroke-like episodes and neurologic deficits. The purpose of this study&#xD;
      is to integrate longitudinal clinical data, radiological data, and blood biomarkers of&#xD;
      Sturge-Weber syndrome patients.&#xD;
&#xD;
      The research aims are:&#xD;
&#xD;
        1. To integrate longitudinal clinical data, radiological data, and blood biomarkers of&#xD;
           Sturge-Weber syndrome patients.&#xD;
&#xD;
        2. Identify plasma and imaging biomarkers sensitive to exacerbation of clinical symptoms&#xD;
           including seizures, headaches, or stroke-like episodes.&#xD;
&#xD;
        3. For enrolled patients who present with severe neurological symptoms screen blood samples&#xD;
           for inflammatory changes.&#xD;
&#xD;
      The target enrollment for this study is about 250 individuals diagnosed with Sturge-Weber&#xD;
      Syndrome. The goal of this study is to understand more about Sturge-Weber Syndrome, the&#xD;
      possible treatments for this disease, and identify targets for clinical trials. Those&#xD;
      participating in the database will be asked to consent to blood draws.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1: Develop a longitudinal database of patients with SWS Clinical sites will collect&#xD;
      longitudinal data retrospectively on measures of clinical symptoms and medications/treatments&#xD;
      for study subjects who participated in the existing BVMC2/SWF registry and consent to&#xD;
      participate in BVMC3 study. Retrospective data will be used to create a longitudinal&#xD;
      dashboard where practitioners can identify predictors of atrisk patients who are most likely&#xD;
      to have a serious neurological symptom and the current treatments. Prospective data&#xD;
      collection: Clinical sites will collect longitudinal data prospectively for at-risk patients&#xD;
      who present with a new, severe neurological symptom.&#xD;
&#xD;
      Aim 2: Examine longitudinal Quantitative MRI Baseline MRI datasets will be collected and&#xD;
      Limited Data Sets (LDS) will be generated and uploaded to a central imaging database from all&#xD;
      participating centers. Subsequent MRI scans will be collected for patients who experience&#xD;
      acute exacerbation of clinical symptoms, including seizures, headaches, or stroke-like&#xD;
      episodes. Integrated imaging data, detailed treatment data, and detailed clinical data&#xD;
      including neurological symptoms, seizures, and headache history will be analyzed.&#xD;
&#xD;
      Aim 3: Collect and Store Blood Samples for Analysis All patients enrolled in BVMC3 study will&#xD;
      have blood samples sent to and stored at University of California San Francisco (UCSF).&#xD;
      Enrolled patients presenting with stroke-like episodes, stroke, headache, or seizure will&#xD;
      have a second blood sample taken at the time of the neurologic symptom and a third sample&#xD;
      taken 6 months later, or even later if symptoms have not resolved within 6 months. Multiplex&#xD;
      angioma and inflammatory marker array will be assessed on all 3 samples from patients at the&#xD;
      same time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Natural history of disease progression.</measure>
    <time_frame>4 years</time_frame>
    <description>Integrative aspect that examines longitudinal associations of clinical symptoms, radiological disease progression, medical treatments, and blood biomarkers.</description>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Sturge-Weber Syndrome</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Assemble a cohort of 250 patients with standardized phenotyping/diagnosis to collect&#xD;
        standardized longitudinal clinical and radiological data and obtain blood samples at&#xD;
        enrollment. We anticipate 25% of 250 enrolled patients will have serious neurological&#xD;
        symptoms.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with MRI-documented unilateral or bilateral leptomeningeal angiomas with or&#xD;
             without neurological symptoms including seizures, headaches, and stroke-like episodes&#xD;
&#xD;
          -  Patients of any age&#xD;
&#xD;
          -  Availability of longitudinal clinical and imaging data from all patient EHR records&#xD;
&#xD;
          -  Consent to being followed prospectively throughout the course of the study&#xD;
&#xD;
          -  Willing to provide blood samples&#xD;
&#xD;
          -  Inclusion criteria to trigger entry into Aim 1B: severe seizures, headaches, or&#xD;
             stroke-like episodes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons without physician diagnosed SWS&#xD;
&#xD;
          -  Persons unwilling to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Loeb, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey Loeb, M.D., Ph.D.</last_name>
    <phone>(312)-996-6496</phone>
    <email>jaloeb@uic.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanbo Holley</last_name>
      <phone>415-502-2151</phone>
      <email>yuanbo.holley@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andres Alvarez Pinzon, Ph.D., M.D., M.H.A.</last_name>
      <email>Andres.AlvarezPinzon@ucsf.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Illinois At Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Loeb, MD, PhD</last_name>
      <phone>312-996-1757</phone>
    </contact>
    <contact_backup>
      <last_name>Veronica Green, BSN, RN</last_name>
      <email>vgreen5@uic.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pooja Vedmurthy</last_name>
      <phone>443-923-9569</phone>
    </contact>
    <contact_backup>
      <last_name>Anne Comi, MD</last_name>
      <email>comi@kennedykrieger.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Pinto, MD, PhD</last_name>
      <phone>616-919-3499</phone>
      <email>Anna.Pinto@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Csaba Juhasz, M.D., Ph.D.</last_name>
      <phone>313-966-5136</phone>
      <email>csaba.juhasz@wayne.edu</email>
    </contact>
    <contact_backup>
      <last_name>Aimee Luat, M.D.</last_name>
      <email>aluat@dmc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Metcalf</last_name>
      <phone>513-636-4266</phone>
      <email>Megan.Metcalf@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Adrienne Hammill, M.D., Ph.D.</last_name>
      <email>Adrienne.Hammill@cchmc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Falke</last_name>
      <phone>614-722-4625</phone>
      <email>Ashley.falke@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Warren Lo, M.D.</last_name>
      <email>warren.lo@nationwidechildrens.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Jeffrey A Loeb</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sturge-Weber Syndrome</mesh_term>
    <mesh_term>Brain Stem Infarctions</mesh_term>
    <mesh_term>Klippel-Trenaunay-Weber Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

